The $2.6 Billion Mistake Nobody Talks About In 2019, a mid-sized generic pharmaceutical company committed $340 million to develop a […]

When AbbVie filed its 132nd patent on adalimumab, the drug that became Humira, the company was not protecting a new

How executives, investors, and analysts use patent cliff intelligence to protect revenue, time acquisitions, and build portfolios that don’t collapse

Patent expiration is the most predictable crisis in pharmaceuticals. The dates are public, the revenue cliffs are calculable, and yet

Drug companies do not simply invent medicines. They engineer legal structures designed to convert twenty years of patent protection into

The Counterintuitive Move That Makes Perfect Business Sense A brand pharmaceutical company holds an approved drug. No generic competitor has

A forensic comparison of the 505(b)(2) and 505(j) regulatory strategies that separate profitable pharmaceutical launches from expensive cautionary tales. The

A forensic guide to pharmaceutical life cycle extension: the IP strategies, regulatory mechanics, and commercial execution frameworks that separate drugs

Somewhere in the patent office’s public records, there is a graveyard. It has no physical address and no memorial plaques,